Compare NRDY & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRDY | NKTX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | 157 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 129.3M |
| IPO Year | N/A | 2020 |
| Metric | NRDY | NKTX |
|---|---|---|
| Price | $1.13 | $1.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $1.25 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 1.5M | 623.5K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $177,867,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.77 | $1.31 |
| 52 Week High | $2.18 | $2.74 |
| Indicator | NRDY | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.39 | 40.56 |
| Support Level | $1.34 | $1.81 |
| Resistance Level | $1.49 | $1.90 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 1.37 | 20.00 |
Nerdy Inc is a curated direct-to-consumer platform for live online learning. Its proprietary platform leverages technology, including artificial intelligence ("AI"), to connect students, users, parents, guardians, and purchasers of all ages to tutors, instructors, subject matter experts, educators, and other professionals. The company provides learning experiences across numerous subjects and multiple formats, including one-on-one instruction, small group tutoring, large format classes, tutor chat, essay review, adaptive assessments, and self-study tools. The company generates revenue by selling services to learners and institutions for one-on-one instruction and small group tutoring.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.